Aurora Labs Updates Placement Terms as 27 Million Shares Move to Tranche 2 at $0.055

Anjali Anand

06 November 2026 11:23 AM AEDT

Aurora Labs Updates Placement Terms as 27 Million Shares Move to Tranche 2 at $0.055

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Aurora Labs Limited (ASX:A3D) has filed an updated Appendix 3B disclosing that 27,000,005 ordinary fully paid shares originally allocated to its Tranche 1 placement settlement have been moved to a Tranche 2 placement, with the proposed issue priced at AUD $0.055 per security and subject to shareholder approval.

Key Points

27,000,005 ordinary fully paid shares to be issued under Tranche 2 of the placement at AUD $0.055 each
The update reflects part of the Tranche 1 placement participants moving to Tranche 2 settlement, as referenced in the 28 October 2026 disclosure
Shareholder approval is required, with the meeting date set for 13 January 2027
Proposed issue date is 22 January 2027

Update to October 2026 Placement Structure

Aurora Labs filed the updated Appendix 3B on 6 November 2026, amending its previous announcement dated 28 October 2026. According to the filing, part of the Tranche 1 placement settlement has been moved to a Tranche 2 placement. The updated filing records 27,000,005 ordinary fully paid shares in the existing security class, priced at AUD $0.055 per share, to be issued for cash consideration in Australian dollars. The filing states the securities will rank equally in all respects from their issue date with existing issued securities in the same class.

Shareholder Approval and Issue Timetable

The proposed Tranche 2 issue is conditional upon shareholder approval under ASX Listing Rule 7.1. The filing identifies a meeting date of 13 January 2027 for the determination of that approval, with the date recorded as estimated. The proposed issue date is set for 22 January 2027. The filing states that a party referred to in Listing Rule 10.11 is not participating in the proposed issue, and that the securities will not be restricted securities or subject to voluntary escrow. No lead manager or broker is recorded, and the issue will not be underwritten.

Disclosed Purposes for the Security Issuance

Aurora Labs disclosed the following purposes for the issuance of securities: expansion of existing production lines; acquisition of commercial off-the-shelf metal additive manufacturing equipment; product readiness; business development and marketing activities; ongoing intellectual property protection; and general working capital. The filing also states that any on-sale of the proposed securities within 12 months of their issue date will comply with the secondary sale provisions of the Corporations Act by virtue of the publication of a cleansing notice. The filing notes that the company's dividend policy will not change if the proposed issue proceeds.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.